California-based precision oncology company Guardant Health has extended its partnership with science and technology company Merck KGaA to leverage its database platform GuardantINFORM. The platform will be used by Merck KGaA to speed up drug discovery and development processes to treat cancer.
GuardantINFORM, a real-world evidence (RWE) platform, comprises over 225,000 clinical and genomic data of patients obtained through the company’s Guardant360 liquid biopsy tests that identified more than 60 types of solid tumor cancers. Under the partnership, Merck KGaA will work with data scientists at Guardant Health on its oncology pipeline using the RWE platform.
Germany-based Merck KGaA operates its biopharmaceutical business in US and Canada as EMD Serono. The company’s healthcare expertise includes areas such as oncology, neurology and immunology, fertility, endocrinology, and general medicine. Further, it builds on strategic partnerships to grow its US business with focused therapies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.